Graft-versus-host Disease
📧 Sign up to get email alerts when something new happens for Graft-versus-host Disease.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-11-06Clinical Trial Update: A Phase I/II Trial of VUM02 Injection for Steroid-refractory Acute Graft-versus-host Disease (SR-aGvHD) Treatment [Phase 1, Phase 2]
A Phase I/II clinical trial of VUM02 injection for steroid-refractory acute graft-versus-host disease is planned, with status not yet recrui…
-
CLINICAL_TRIALS trial_result · 2024-10-29Clinical Trial Update: Glasdegib for Chronic Graft-Versus-Host Disease [Phase 1, Phase 2]
A Phase 1/2 clinical trial update reports termination of the glasdegib study for chronic graft-versus-host disease (and fasciitis) with resu…
-
CLINICAL_TRIALS research · 2024-10-17Clinical Trial Update: MaaT013 As Salvage Therapy in Ruxolitinib Refractory GI-aGVHD Patients [Phase 3]
Phase 3 clinical trial evaluating MaaT013 as salvage therapy for ruxolitinib-refractory gastrointestinal acute graft-versus-host disease; th…
-
CLINICAL_TRIALS trial_result · 2024-10-10Clinical Trial Update: A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD) [Phase 2]
A Phase 2 study of axatilimab at three doses in chronic graft-versus-host disease has posted results; the trial is currently active but not …
-
CLINICAL_TRIALS trial_result · 2024-10-02Clinical Trial Update: Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation [Phase 2]
Phase 2 trial comparing cyclophosphamide plus abatacept with standard of care after allogeneic stem cell transplantation for graft-versus-ho…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2024-10-01Clinical Trial Update: Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD) [Phase 1]
This update reports the completion of a Phase 1 trial evaluating Neihulizumab for standard-risk acute graft-versus-host disease.
-
CLINICAL_TRIALS trial_result · 2024-10-01Clinical Trial Update: Ruxolitinib and Steroid As First Line Therapy for Acute GVHD [Phase 2]
Phase 2 trial evaluating ruxolitinib in combination with a steroid as first-line therapy for acute graft-versus-host disease has been termin…
-
CLINICAL_TRIALS research · 2024-09-25Clinical Trial Update: A Clinical Study of Bacillus Coagulans in Acute Graft-Versus-Host Disease After Hematopoietic Stem Cell Transplantation [NA]
This clinical trial update describes a study of Bacillus coagulans for acute graft-versus-host disease following hematopoietic stem cell tra…
-
CLINICAL_TRIALS trial_result · 2024-09-20Clinical Trial Update: Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment
This completed clinical trial (NCT01460914) reports outcomes of extracorporeal photopheresis treatment for cutaneous T-cell lymphoma and gra…
-
CLINICAL_TRIALS research · 2024-08-30Clinical Trial Update: Ixazomib in the Prophylaxis of Chronic Graft-versus-host Disease. [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating ixazomib for prophylaxis of chronic graft-versus-host disease after hematopoietic stem cell transplantat…
-
CLINICAL_TRIALS trial_result · 2024-08-28Clinical Trial Update: Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
Clinical trial update on MaaT013 for an Early Access Program in steroid-refractory acute graft-versus-host disease of the intestine. The spo…
-
CLINICAL_TRIALS trial_result · 2024-08-27Clinical Trial Update: A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002) [Phase 3]
A Phase 3 study comparing T-Guard vs ruxolitinib for steroid-refractory acute graft-versus-host disease has been terminated, with results po…
-
CLINICAL_TRIALS trial_result · 2024-08-23Clinical Trial Update: Chimeric Natural Killer Receptor-Universal T Cells for Refractory GVHD [Phase 1]
A Phase 1 trial evaluating Chimeric Natural Killer Receptor-Universal T Cells for refractory graft-versus-host disease is currently recruiti…
-
FDA approval · 2024-08-14FDA Approved: NIKTIMVO — Original Application (Incyte Corporation)
FDA approved NIKTIMVO (axatilimab-csfr) from Incyte in an original Biologics License Application for the treatment of chronic graft-versus-h…
-
CLINICAL_TRIALS other · 2024-08-12Clinical Trial Update: A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD) [Phase 2]
Phase II clinical trial ABSK021 (Pimicotinib) for chronic graft-versus-host disease is currently enrolling by invitation.
-
CLINICAL_TRIALS trial_result · 2024-08-02Clinical Trial Update: Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD [Phase 1, Phase 2]
Update on a Phase 1/2 dose-finding trial of pentostatin for injection for steroid-refractory acute graft-versus-host disease; the study is t…
-
CLINICAL_TRIALS research · 2024-07-29Clinical Trial Update: Comparison of Different Dose of Anti-T Lymphocyte Globulin (ATLG) in Haploidentical HSCT for GVHD Prophylaxis [Phase 3]
A Phase 3 clinical trial evaluating different doses of anti-T lymphocyte globulin (ATLG) for graft-versus-host disease prophylaxis in haploi…
-
CLINICAL_TRIALS withdrawal · 2024-07-23Clinical Trial Update: Electron Beam Radiotherapy for the Treatment of Refractory Sclerodermatous Chronic Graft Versus Host Disease [EARLY_Phase 1]
The EARLY Phase 1 trial of Electron Beam Radiotherapy for refractory sclerodermatous chronic graft-versus-host disease (NCT05515692) has bee…
-
CLINICAL_TRIALS trial_result · 2024-07-15Clinical Trial Update: The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease [EARLY_Phase 1]
This early-phase 1 study evaluated the safety and potential effects of 5% lifitegrast ophthalmic solution in subjects with dry eye disease a…
-
CLINICAL_TRIALS research · 2024-07-08Clinical Trial Update: Low-dose Cyclophosphamide or CNI in the Prevention of Acute Graft-versus-host Disease After gDLI [NA]
A clinical trial is evaluating whether low-dose cyclophosphamide or a calcineurin inhibitor can prevent acute graft-versus-host disease afte…
-
CLINICAL_TRIALS trial_result · 2024-06-28Clinical Trial Update: Effectiveness and Safety of a Single-Center Clinical Study on a CD25 Monoclonal Antibody-Containing GVHD Prophylaxis Scheme to Reduce the Incidence of Severe Acute GVHD After Umbilical Cord Blood Transplantation for Malignant Hematologic Diseases [Phase 2]
Phase 2 clinical trial evaluating a CD25 monoclonal antibody–containing GVHD prophylaxis to reduce severe acute GVHD after umbilical cord bl…
-
CLINICAL_TRIALS other · 2024-06-25Clinical Trial Update: Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHD [Phase 2]
Phase 2 trial update on first-line therapy for acute graft-versus-host disease using a combination of steroids and a humanized anti-CD25 mon…
-
CLINICAL_TRIALS trial_result · 2024-06-21Clinical Trial Update: Effect of PMSCs and Their Secretome for the Treatment of GvHD [Phase 3]
A Phase 3 study evaluated placental mesenchymal stem cells (PMSCs) and their secretome for the treatment of graft-versus-host disease; the t…
-
CLINICAL_TRIALS trial_result · 2024-06-13Clinical Trial Update: Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease [Phase 1]
This Phase 1 clinical trial evaluated abatacept as prophylaxis against graft-versus-host disease after hematopoietic stem cell transplantati…
-
FDA label_change · 2024-06-04FDA Approved: BRUKINSA — Supplemental Application (BeOne Medicines USA, Inc.)
FDA approved a supplemental application for BRUKINSA (zanubrutinib) to update the product labeling.